Langsjoen P H, Vadhanavikit S, Folkers K
Drugs Exp Clin Res. 1985;11(8):577-9.
Nineteen patients with chronic myocardial disease (NYHA Classes III and IV) were given Coenzyme Q10 in a controlled double-blind cross-over study. All had either low or borderline levels of CoQ10 in their blood, and showed a significant change into the normal range with oral CoQ10 replacement. Eighteen patients reported improvement in activity tolerance with replacement therapy. Combined clinical observations, stroke volume measured by impedance cardiography, and ejection fractions calculated from systolic time intervals, all showed significant improvement in parallel with CoQ10 administration. This application of the principles of bioenergetics introduces a promising new dimension to the study and treatment of the complex problem of myocardial failure.
在一项对照双盲交叉研究中，对19名慢性心肌病患者（纽约心脏协会心功能分级为III级和IV级）给予辅酶Q10。所有患者血液中的辅酶Q10水平均较低或处于临界值，口服补充辅酶Q10后，其水平显著变化至正常范围。18名患者报告替代疗法使活动耐量有所改善。综合临床观察、通过阻抗心动图测量的每搏输出量以及根据收缩期时间间期计算的射血分数，均显示与给予辅酶Q10平行出现显著改善。生物能量学原理的这种应用为心肌衰竭这一复杂问题的研究和治疗引入了一个有前景的新维度。
